54 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 redirecting immune cells against tumour cells has demonstrated early clinical success. As clinical pipelines mature, multi-specific antibodies could redefine standards of care in complex diseases. Finally, the biosimilar market is poised for significant growth as key patents expire later this decade. By 2027, products such as Sylvant (siltuximab) and Portrazza (necitumumab) will face competition, followed in 2028 by Opdivo (nivolumab) and Tecentriq (atezolizumab). Between 2029 and 2030, additional blockbusters like Ocrevus, Imfinzi, Bexxar, Illumetri, Emgality and Arzerra will lose exclusivity. This wave of expirations will expand patient access by delivering lower-cost alternatives, while intensifying competition and driving efficiency across the biopharma value chain. For Mabion, this represents a significant opportunity to leverage our biologics expertise to support both innovators and biosimilar developers in bringing these therapies to market. MM. Again, there are two areas in particular which lots of people are focusing on and indeed where we are increasing capacity and capability to support our customers: GLP-1 peptides and ADCs. Both are high-growth, high-complexity segments where demand is expanding faster than supply. But while it’s natural to be excited about new modalities, we should not forget that small molecules still represent the vast majority not only of the medicines that patients use today, but of the drugs of the future too. That’s why we continually work to strengthen our small molecule capacity. This aligns with our investment strategy. We’re not just expanding capacity for its own sake, we’re tailoring it to where customers need us most, supporting both the breakthroughs of tomorrow and the essential therapies of today. That relentless focus on customer needs ensures our growth is sustainable, strategic and directly linked to the success of the world’s leading innovators. EK. We’re seeing significant growth in the field of nasal drug delivery, particularly with the emergence of nose to brain delivery technologies. Traditionally used for localised conditions such as allergies or congestion, nasal sprays are now being developed to target central nervous system (CNS) disorders, pain management and even neurodegenerative diseases. A major driver of this innovation is the growing body of research supporting direct nose to brain delivery pathways. One notable example is the Wake Forest study that successfully mapped the olfactory and trigeminal nerve pathways, key routes for delivering therapeutics directly to the brain. These findings are opening doors to new indications previously limited by the blood brain barrier. As a CDMO with extensive expertise in nasal spray development and manufacturing, Renaissance Lakewood is wellpositioned to support our partners with exploring these cutting-edge applications. We’re seeing increasing interest from our clients in exploring both new chemical entities via nasal spray delivery, as well as reformulation to nasal of existing small molecule drugs. With the convergence of novel formulations, new excipients and device advancements, nasal drug delivery is evolving into a versatile platform for CNS and systemic therapies. We anticipate this modality will continue to grow across a wide range of therapeutic areas, from psychiatry to neuroinflammation and rare diseases. LS. We’re seeing significant growth in ATMPs, particularly cell and gene therapies. These areas demand highly controlled manufacturing environments and impeccable contamination control, which aligns well with our core capabilities. We’re also seeing increased activity in oncology and rare diseases, where the pressure to innovate and scale quickly creates opportunities for agile, quality-driven partners like us. How is the increasing demand for patient-centric care influencing your business strategy? PV. Patient-centric care means focusing not only on therapeutic efficacy, but also on accessibility, convenience and long-term support throughout the treatment journey. For us, that translates into developing delivery formats that enable athome use, building stronger collaborations with patient organisations and integrating digital health solutions to improve adherence and monitoring. Bringing the patient’s voice into the development process at an early stage is central to our strategy. ML. Patient-centricity is fundamentally reshaping how nucleic acid therapeutics are developed and delivered, and it directly informs Hongene’s strategy. Patients expect high-quality medicines ERIC KANEPS Vice President, Sales & Marketing Renaissance Lakewood ROUNDTABLE
RkJQdWJsaXNoZXIy MjY2OTA4MA==